Lingkang Pharmaceutical expects to achieve a net profit attributable to shareholders of around 23 million yuan in the first half of 2026, compared with a loss of 35.7337 million yuan in the same period last year, swinging to a profit year-on-year. The company said the turnaround was mainly due to stepping up promotion of products that won centralized procurement bids, leveraging channel advantages to expand the market for non-centralized-procurement products, and deepening pharmaceutical distribution and agency business by relying on the strengths of its sales system, which drove improved operating performance.
Lionco Pharm Grp Co LtdExpects net profit turnaround to ~23M yuan from a loss, driven by product promotion and channel expansion.